NEWS AND PRESS
PRESS RELEASE: Reapplix Receives Innovative Technology Contract from Vizient for the 3C Patch® Wound Management System
Reapplix announced its 3C Patch® Wound Management System has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven healthcare performance improvement company. The contract was awarded based on the recommendation of 3C Patch by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the healthcare industry.
PRESS RELEASE: REAPPLIX RECEIVES CODING AND REIMBURSEMENT DETAILS FOR 3C PATCH® IN THE US – ALL OBSTACLES REMOVED FOR COMMERCIAL EXECUTION
Reapplix, a privately-held, regenerative medicine company today announces, that coding details and reimbursement level have been set for its autologous platelet-rich plasma product 3C Patch® for the treatment of chronic non-healing diabetic wounds for up to 20 weeks. The completion of the transmittal follows the announcement of National Coverage Determination (NCD) in April 2021.
Press Release: Former Urgo Medical Exec Kira Rupprecht Joins Reapplix as Chief Executive Officer
The Board of Directors of Reapplix, a company specializing in the biological treatment and management of diabetic foot ulcers, has appointed Kira Rupprecht as its new Chief Executive Officer, effective immediately. She will focus on expanding access to the company’s innovative 3C Patch® System, a biological wound therapy product made entirely from the patient’s own blood, in the U.S. and other priority markets around the world.
PRESS RELEASE: A FINAL MEDICARE NATIONAL COVERAGE DETERMINATION HAS BEEN PUBLISHED ENABLING SUSTAINABLE US REIMBURSEMENT FOR REAPPLIX’s 3C PATCH®
Reapplix announces that a final National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services (CMS) has secured coverage for the company’s 3C Patch® system. The NCD describes the coverage of autologous platelet-rich plasma for the treatment of chronic, non-healing diabetic wounds for up to 20 weeks.
PRESS RELEASE: REAPPLIX ANNOUNCES APPOINTMENT OF RICHARD TWOMEY TO BOARD OF DIRECTORS
Reapplix is today very pleased to be able to announce that Richard Twomey has been appointed to the Board of Directors. Mr. Twomey is a highly respected healthcare executive who for the past six years, to September 2020, has held the position of CEO and President of...
PRESS RELEASE: REAPPLIX RECEIVES NEW REIMBURSEMENT CODING AND COMPLETES USD 22.6M EQUITY FINANCING TO DRIVE US COMMERCIALIZATION
Reapplix announces that it has successfully received Medicare reimbursement coding instructions from the Centers for Medicare and Medicaid Services (CMS) with a national average payment rate of USD 1,622.74. The rate covers each patient visit to Hospital Outpatient Departments to receive 3C Patch® therapy for hard-to-heal diabetic foot ulcers.
SmartTrak market analysis highlights Reapplix strong clinical data
SmartTRAK, the leading provider of market data and analysis for the wound and regenerative medicine markets, recently reported on current trends and the focus on differentiation in the wound care space. The report noted that Biologics is garnering attention through data and stated that “Autologous solutions for hard-to-heal wounds are gaining attention.
PRESS RELEASE: Reapplix 3C Patch® therapy recommended for enhancement of healing diabetic foot ulcers by international working group on the diabetic foot (IWGDF)
The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of Reapplix’s technology, the 3C Patch®, an autologous combined leucocyte, platelet and fibrin, as an adjunctive treatment.
Reapplix strengthens its Board of Directors and adds experienced profiles
Reapplix has elected additional board members to support and accelerate the company’s development. The newly elected board members bring substantial international competencies and comprehensive experience within business development, commercialisation, funding, operational excellence, financial management, auditing, risk management and corporate governance.
Patient thanks clinical trial team for saving his leg from amputation and calls 3C Patch® amazing
A UK self-employed driver and mechanic faced amputation but his ulcer healed and his leg was saved.
SmartTrak market analysis highlights Reapplix strong clinical data
SmartTRAK, the leading provider of market data and analysis for the wound and regenerative medicine markets, recently reported on current trends and the focus on differentiation in the wound care space. The report noted that Biologics is garnering attention through data and stated that “Autologous solutions for hard-to-heal wounds are gaining attention.
Reapplix strengthens its Board of Directors and adds experienced profiles
Reapplix has elected additional board members to support and accelerate the company’s development. The newly elected board members bring substantial international competencies and comprehensive experience within business development, commercialisation, funding, operational excellence, financial management, auditing, risk management and corporate governance.
Patient thanks clinical trial team for saving his leg from amputation and calls 3C Patch® amazing
A UK self-employed driver and mechanic faced amputation but his ulcer healed and his leg was saved.
3C PATCH® WILL BE THE NEW NAME FOR LEUCOPATCH® IN 2019
Based on the positive clinical results documented in the outcome data (recently published in The Lancet Diabetes & Endocrinology) of a major international randomized controlled trial of our LeucoPatch® wound healing technology, Reapplix’s primary focus now shifts from development to commercialization.
Dr. Magnus Löndahl presented Clinical experiences with LeucoPatch and the status of the large RCT at the Innovations in Wound Healing meeting.
MD, PhD Magnus Löndahl one of 4 principal investigators of the large randomized controlled trial of LeucoPatch/3C Patch on diabetic foot ulcers presented “Clinical experiences with LeucoPatch and status of the large RCT: Leucopatch™ System in the Management of Hard-To-Heal Diabetic Foot Ulcers” at the 4th annual Innovations in Wound Healing meeting December 9th 2017 in Bimini, Bahamas.
Reapplix scientific team presented data at The Diabetic Lower Extremity Symposium
Data were presented in a poster format and was titled: “3C Patch derived autologous immune cells delivers immune responses appropriate for the treatment of Diabetic Foot Ulcers”
Reapplix presents poster at Diabetic Foot Study Group meeting in Porto
The Reapplix team have the pleasure to participate at the 14TH ANNUAL MEETING OF THE DFSG, 8-10 September 2017.
New paper published studying the impact of LeucoPatch in chronic wounds
As each LeucoPatch contains a substantial number of leucocytes, the aim of the study was to investigate the activity of the polymorphonuclear neutrophils (PMNs) within the LeucoPatch.
Key patents granted in Europe and Eurasia
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in Europe and in Eurasia.
Patent news – Patent granted in Japan
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted in the Japan.
PRESS RELEASE: Reapplix Receives Innovative Technology Contract from Vizient for the 3C Patch® Wound Management System
Reapplix announced its 3C Patch® Wound Management System has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven healthcare performance improvement company. The contract was awarded based on the recommendation of 3C Patch by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the healthcare industry.
PRESS RELEASE: REAPPLIX RECEIVES CODING AND REIMBURSEMENT DETAILS FOR 3C PATCH® IN THE US – ALL OBSTACLES REMOVED FOR COMMERCIAL EXECUTION
Reapplix, a privately-held, regenerative medicine company today announces, that coding details and reimbursement level have been set for its autologous platelet-rich plasma product 3C Patch® for the treatment of chronic non-healing diabetic wounds for up to 20 weeks. The completion of the transmittal follows the announcement of National Coverage Determination (NCD) in April 2021.
Press Release: Former Urgo Medical Exec Kira Rupprecht Joins Reapplix as Chief Executive Officer
The Board of Directors of Reapplix, a company specializing in the biological treatment and management of diabetic foot ulcers, has appointed Kira Rupprecht as its new Chief Executive Officer, effective immediately. She will focus on expanding access to the company’s innovative 3C Patch® System, a biological wound therapy product made entirely from the patient’s own blood, in the U.S. and other priority markets around the world.
PRESS RELEASE: A FINAL MEDICARE NATIONAL COVERAGE DETERMINATION HAS BEEN PUBLISHED ENABLING SUSTAINABLE US REIMBURSEMENT FOR REAPPLIX’s 3C PATCH®
Reapplix announces that a final National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services (CMS) has secured coverage for the company’s 3C Patch® system. The NCD describes the coverage of autologous platelet-rich plasma for the treatment of chronic, non-healing diabetic wounds for up to 20 weeks.
PRESS RELEASE: REAPPLIX ANNOUNCES APPOINTMENT OF RICHARD TWOMEY TO BOARD OF DIRECTORS
Reapplix is today very pleased to be able to announce that Richard Twomey has been appointed to the Board of Directors. Mr. Twomey is a highly respected healthcare executive who for the past six years, to September 2020, has held the position of CEO and President of...
PRESS RELEASE: REAPPLIX RECEIVES NEW REIMBURSEMENT CODING AND COMPLETES USD 22.6M EQUITY FINANCING TO DRIVE US COMMERCIALIZATION
Reapplix announces that it has successfully received Medicare reimbursement coding instructions from the Centers for Medicare and Medicaid Services (CMS) with a national average payment rate of USD 1,622.74. The rate covers each patient visit to Hospital Outpatient Departments to receive 3C Patch® therapy for hard-to-heal diabetic foot ulcers.
PRESS RELEASE: Reapplix 3C Patch® therapy recommended for enhancement of healing diabetic foot ulcers by international working group on the diabetic foot (IWGDF)
The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of Reapplix’s technology, the 3C Patch®, an autologous combined leucocyte, platelet and fibrin, as an adjunctive treatment.
PRESS RELEASE: Reapplix wins EY Entrepreneur Of The Year award in the Life Science category
As the Reapplix team proudly received the prestigious EY Entrepreneur Of The Year award in the Life Sciences category at the annual gala event in Copenhagen, Denmark on November 29, 2018, the jury emphasised the big market potential and innovative approach to wound healing deployed by Reapplix:
PRESS RELEASE: New help on the way for people with diabetic foot ulcers
A major international randomized controlled trial (RCT) has just been published in the internationally recognized journal The Lancet Diabetes & Endocrinology and documents the effect of a new treatment, LeucoPatch®, which offers significant enhancement of healing of hard-to-heal foot ulcers.
PRESS RELEASE: Positive outcome data of large Randomized Controlled Trial presented at American Diabetes Association Scientific Sessions & Reapplix business update
Reapplix ApS, the regenerative medicine company, initially focussed on chronic wounds, announces that positive outcome data of an independent Randomized Controlled Trial (RCT) of its LeucoPatch® wound healing platform was presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando, Florida. The Company has also provided an update on the Company’s progress.